DOJ to Lead Review of DoorDash’s $17 Billion Instacart Deal
The review comes with a conditional $1.25 billion termination payment for DoorDash if specified competition-law obstacles block the deal.
Stocks
Markets, companies and the economy, from New York and Frankfurt to Istanbul and Tokyo.
2,053 stories
The review comes with a conditional $1.25 billion termination payment for DoorDash if specified competition-law obstacles block the deal.
Stocks
Stocks3 sources
Stocks3 sources
The software group targets double-digit revenue and EPS growth in 2029, citing subscription momentum and plans to expand AI monetization.
Stocks
The company’s restructuring includes layoffs and spending cuts across several divisions as it seeks to reduce annual costs.
Stocks
GPS reduced the risk of death by 41% versus best available treatment, and SELLAS plans FDA discussions and BLA preparations.
Stocks
Nvidia reduced its Nokia and Intel holdings in the third quarter, unsettling investors as both companies’ shares came under pressure.
Stocks3 sources
The home services company is raising fresh capital, with ₹600 crore earmarked for InstaHelp and nearly ₹540 crore for marketing.
Stocks
The Finnish satellite technology company’s voluntary offer covers all of Avio and includes commitments on its Italian identity and workforce.
Stocks
The bank sees Türkiye likely to retain its emerging-market status and names BİM among its favored regional stocks.
Stocks2 sources
The company plans to issue bonds or finance bills in one or more domestic sales over a year, subject to regulatory approval.
Stocks
Der Spiegel says 15 million emails and documents expose financial dealings involving politicians, oligarchs and other prominent figures.
Stocks2 sources
A missed payment on a 7.5 billion-lira lease certificate prompted JCR Avrasya to cut Peker GYO's ratings to default-level grades.
Stocks
The approval gives adults with polymyalgia rheumatica who struggle with corticosteroids a new treatment option, following positive Phase III results.
Stocks
The oral drug, used with everolimus, cut the risk of disease progression or death by 62% in a Phase III trial’s ESR1-mutated group.
Stocks